Nimesulide (Nise) granules for oral 100 mg – [9 sachets]

Description

Nais Pharmacodynamics
Nimesulide is a non-steroidal anti-inflammatory agent of the class of sulfonamides.
It has anti-inflammatory, analgesic and antipyretic effects. Unlike non-selective NSAIDs, nimesulide mainly inhibits cyclooxygenase-2 (COX-2), inhibits the synthesis of prostaglandins in the inflammation focus; it has less pronounced inhibitory effect on cyclooxygenase-1 (COX-1).

Indications
Acute pain (backache, lower back pain; pain syndrome in musculoskeletal system, including bruises, sprains and dislocations; tendinitis, bursitis: toothache).
Symptomatic treatment of osteoarthritis (osteoarthritis) with pain syndrome.
Primary algodysmenorrhea.
The drug is intended for symptomatic therapy, reducing pain and inflammation at the time of use; nimesulide is recommended for therapy as a second-line drug.

Contraindications
Hypersensitivity to nimesulide or other components of the drug.
History of hyperergic reactions (bronchospasm, rhinitis, urticaria) associated with the use of acetylsalicylic acid or other NSAIDs, including nimesulide.
Complete or incomplete combination of bronchial asthma, recurrent nasal or paranasal sinus polyposis with intolerance to acetylsalicylic acid and other NSAIDs (including history);
Hepatotoxic reactions to nimesulide in the history.
Concomitant use with other drugs with potential hepatotoxicity (e.g. other NSAIDs).
Chronic inflammatory bowel disease (Crohn’s disease, ulcerative colitis) in the acute phase.
The period after aortocoronary bypass surgery.
Fever syndrome in colds and acute respiratory viral infections.
Suspicion of acute surgical pathology.
Gastric or duodenal ulcer in the acute phase; erosive-ulcerous lesions of the gastrointestinal tract; perforations or gastrointestinal bleeding in the anamnesis.
Cerebrovascular bleeding in history or other diseases accompanied by increased bleeding.
Severe clotting disorders.
Severe heart failure.
Severe renal failure (creatinine clearance <30 ml/min), confirmed hyperkalemia.
Liver failure or any active liver disease.
Alcoholism, drug addiction.
Hereditary fructose intolerance, sucrose-isomaltase deficiency and glucose-galactose malabsorption syndrome.
Pregnancy and breastfeeding.
Children under 12 years of age.

Dosage and administration administration

• Inside. The contents of the sachet is dissolved in about 100 ml of water at room temperature (white or light yellow suspension is formed).
• Prepared solution must not be stored.
• Nais® is used only for treatment of patients over 12 years of age.
• Adults and children over 12 years of age
• Take 1 sachet twice a day, after meals.
• Elderly patients
  When treating elderly patients, the necessity of correcting the daily dose is determined by the physician, taking into account the possibility of interaction with other drugs.
• Patients with renal insufficiency
  In patients with renal insufficiency of mild to moderate degree of severity (creatinine clearance 30-60 ml/min) the dose adjustment is not required, while in patients with severe renal insufficiency (creatinine clearance <30 ml/min) the use of nimesulide is contraindicated.
• Patients with hepatic insufficiency.
  Administration of nimesulide in patients with hepatic insufficiency is contraindicated.
• To reduce the likelihood of side effects, it is recommended to take the minimum effective dose for the shortest possible time. The maximum daily dose for adults and children over 12 years is 200 mg. Maximum duration of treatment course is 15 days.